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Together
we heal
How the Leading Together
campaign is turning
hope into reality

outlook.wustl.edu

Outlook 3

A letter from the dean

W

hen I came to Washington University School of Medicine
as executive vice chancellor and dean in 2015, Leading
Together was charging full steam ahead. It was inspiring to see
philanthropic support for the school, already at a remarkable
level, soar to even greater heights. I am deeply grateful to
everyone involved in the campaign for joining with us to
pursue the vision of advancing human health.
I’d like to take a moment to thank members of the
Washington University Board of Trustees, the School of
Medicine National Council, the School of Medicine campaign
committee, our Eliot Society committee, the Washington
University Medical Center Alumni Association executive
council, and the many other alumni volunteers who provided crucial
leadership during the campaign. You helped steer the School of Medicine
through the campaign’s goals and successful conclusion.
We face clear challenges as we look to the future of medicine. However,
we also are poised to continue exceptional work and to make bold moves that
will keep the School of Medicine at the forefront of biomedicine and health
care. Many, many donors — from our loyal annual fund supporters, to those
who invest in the leaders of tomorrow through scholarships, to those who
have made a significant impact on faculty by funding research, professorships,
facilities and centers — have made this possible. These individuals have
helped position us to explore new partnerships, rethink our curriculum for
new generations, build our excellent faculty practice, enhance and improve
diversity, develop physician-scientists, and improve the already extraordinary
breadth and depth of our collaborative research. This will translate into
discoveries that will ultimately benefit patients here and around the world.
Together, we can pursue a future in which discoveries reach patients
sooner. Together, we can realize the dream of personalized medicine. Together,
we can continue to generate the resources needed to transform health care.
Thank you for giving us the momentum to aim for the highest of ideals at
Washington University School of Medicine. It’s an amazing place to be, and
I’m so excited and fortunate to be a part of it.

Sincerely,
David H. Perlmutter, MD
George and Carol Bauer Dean, School of Medicine
Spencer T. and Ann W. Olin Distinguished Professor
Executive Vice Chancellor for Medical Affairs
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Together, we heal.
T

his issue of Outlook is a special one.

It documents the conclusion of Leading Together:
The Campaign for Washington University.
The campaign, which ended this summer, raised an
unprecedented $1.85 billion for the School of Medicine in the
most successful campaign in school history. The campaign has
established 281 endowed scholarships, produced 73 named
professorships, and generated $1.34 billion for research.
These contributions have huge real-life import. They allow
gifted students to attend a world-class medical school and learn
from extraordinary faculty. And they allow leading researchers to
find solutions for some of medicine’s most intractable problems.
Those things are happening now, and, because of the generosity
of donors, will continue to happen.
In this issue, we’ll look at four areas of research the
campaign has significantly advanced. They are:

Alzheimer’s

Mental illness

Cancer

Microbiome

Prevention, early
diagnosis and treatment
of Alzheimer’s disease

New medications for
mental illnesses, such
as depression, anxiety
and schizophrenia

Targeted therapies
that harness the
patient’s own immune
system to fight cancer

Improved understanding
of the human microbiome
to address a host of
health problems

We’ll introduce you to the researchers who are advancing
medicine in these areas, and, because the campaign was about
looking forward, we’ll show you what the future holds.

outlook.wustl.edu
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New hope for
old disease
Doctors may soon be able to predict,
prevent Alzheimer’s disease
B Y TA M A R A B H A N DA R I

Caring for an aging relative with Alzheimer’s disease,
watching memories slowly slip away, is an exhausting
and heartbreaking ordeal. For those with the condition,
modern medicine can offer little in the way of treatment
as the disease inexorably strips away their ability to
recognize and understand the world around them.
Finding solutions can’t happen soon enough. The
American population is rapidly graying, and the risk
of developing the disease rises with advancing age.
The Alzheimer’s Association predicts that 16 million
Americans will be living with the disease by 2050.
A large, dedicated team at Washington University
School of Medicine has been working for 40 years to
brighten this bleak outlook, and the investigators may be on
the cusp of succeeding. They have traced the natural history
of the disease, studied the molecular and cellular changes
that occur in the brain, designed and tested investigational
drugs aimed at slowing or stopping the disease, and
developed imaging techniques to detect toxic proteins in
the brain. Now, they are on the brink of finding ways to
predict who will get the disease and when; they may even
determine how to prevent it entirely.
An Alzheimer’s-free future has never looked more likely.
4 Washington University School of Medicine
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Randall J. Bateman, MD, examines
Taylor Hutton, a participant in a
global multicenter study testing
drugs that may delay or prevent
Alzheimer’s onset. An active
Alzheimer’s advocate, Hutton
attends and speaks at awareness
events and wears an Alzheimer’s
awareness tattoo on her foot.
outlook.wustl.edu
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Step one: diagnosis

MARK KATZMAN

Research by David M.
Holtzman, MD, has
focused on how levels of
the Alzheimer’s proteins
amyloid beta and tau in
the brain and spinal fluid
are linked to risk for and
progression of the disease.

The first sign is usually forgetfulness — a forgotten
conversation, a misplaced item, a question asked
and answered and asked again. Until a few decades
ago, such lapses might have been chalked up to the
normal effects of aging. But Leonard Berg, MD, a
professor of neurology at Washington University,
was concerned that the distinction between normal
aging and dementia was poorly understood, so in
1972 he started a faculty lunch group to discuss
how to distinguish the two processes.
“At the time, there was no standard method
to distinguish normal aging from very mild
dementia,” said John C. Morris, MD, the Harvey
A. and Dorismae Hacker Friedman Distinguished
Professor of Neurology and professor of pathology
and immunology. “So Leonard and his colleagues
developed a clinical tool to diagnose dementia and
to determine its severity.”
That tool, the Clinical Dementia Rating Scale,
later revised by Morris, is now used worldwide
to identify people with dementia. Berg died in
2007; but the work he started has since grown into
Washington University’s Charles F. and Joanne
Knight Alzheimer’s Disease Research Center
(Knight ADRC), a network, directed by Morris,
of faculty members, trainees and staff dedicated to
understanding, treating and preventing the No. 1
cause of cognitive decline in older people.
Today, we know that memory lapses could be
caused by many things: lack of sleep, medications,
vitamin deficiencies, brain tumors or neurological
diseases other than Alzheimer’s, such as Parkinson’s
disease or frontotemporal dementia.
“When people come in and they’re clearly
impaired but we don’t know what the cause is,

that’s when biomarkers can be really useful,”
said Anne Fagan, PhD, a professor of neurology
and head of the biomarker research unit at the
Knight ADRC. Biomarkers are proteins or other
biomolecules that indicate the presence of disease.
Research by Fagan and others has established
that two proteins linked to Alzheimer’s disease
— amyloid beta and tau — can be detected in the
cerebrospinal fluid that bathes the brain and spinal
cord. Neurologists can resolve a difficult diagnosis
by taking a spinal tap and measuring levels of the
two proteins.
“I use the results of these biomarker tests to
inform the care of my patients,” said Gregory S.
Day, MD, an assistant professor of neurology.
“A few decades ago, Alzheimer’s was formally
diagnosed only on autopsy. Now using biomarkers
or imaging, we can tell people what is going on
very early in the process.”

Stopping the disease
in its tracks
Early detection allows physicians to discuss
lifestyle modifications and financial arrangements
with patients. It does not, however, allow them to
offer any medications to slow or stop the disease.
The Food and Drug Administration has not yet
approved any such drugs.
6 Washington University School of Medicine
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David M. Holtzman, MD, the Andrew B. and
Gretchen P. Jones Professor, head of the Department
of Neurology and professor of developmental
biology, is trying to change that. He studies the
basic biology underlying Alzheimer’s disease —
how amyloid beta and tau build up in the brain,
why clumps of such proteins cause brain cells to
die, and how drugs can be designed to interrupt the
process. The research of Holtzman and colleagues
at Eli Lilly and Company led to the development of
solanezumab, a drug designed to counter amyloid
beta’s toxic effects. Solanezumab and another drug,
gantenerumab, are now being evaluated in the firstever Alzheimer’s disease prevention trial, at the
School of Medicine and elsewhere.
Other drugs — targeting amyloid beta or tau —
also are being tested, and researchers are hopeful
that some will prove effective.
In the past, drug trials were complicated by a
lack of accurate disease detection methods.
Then in the early 2000s, Tammie L.S.
Benzinger, MD, PhD, the Knight ADRC’s director
of imaging studies, and others pioneered the use
of positron emission tomography (PET) brain
scans targeted against amyloid beta as a tool for
detecting Alzheimer’s.
“When people started using amyloid PET to
assess trial participants, they discovered that only
about 80 percent of the participants actually had
Alzheimer’s,” said Benzinger, a professor of radiology
and of neurological surgery. “If you treat someone
outlook.wustl.edu

whose dementia is not related to amyloid with an
amyloid drug, of course it’s not going to work.”
Now, clinical trials routinely screen for
misdiagnosed participants using amyloid PET
scans or biomarker analysis.
In addition, researchers are expanding the basic
science foundation upon which drug development
rests. But much of what we know about Alzheimer’s
disease has been learned from studying only one
part of the American population.
“There is a lot of mistrust in the AfricanAmerican community because of a history of

Tammie L.S. Benzinger,
MD, PhD, prepares to
scan a patient with
PET imaging. She and
colleagues pioneered
the use of PET to
detect Alzheimer’s.

Researchers here are pursuing treatments
that could one day dramatically improve
the lives of millions of individuals
worldwide. We want to do our part to
fulfill that goal.”
		— the late Charles F. Knight, former Trustee
Charles F. and Joanne Knight’s extraordinary campaign
support included a major commitment to name The
Charles F. and Joanne Knight Alzheimer’s Disease
Research Center.
Outlook 7

“We’ve found that the concentration of
tau protein is significantly lower in AfricanAmericans than in non-Hispanic whites,” Morris
said. “What does that mean in terms of the
pathology of the disease? I don’t know. But I do
know it means that we can’t just take everybody
and lump them together. The disease may develop
and progress differently in different populations.
We are not going to find treatments that work for
all people if we don’t understand how the disease
behaves in all people.”

Detecting the silent phase

Anne Fagan, PhD,
observes staff scientist
Matthew R. Amos as he
processes samples in her
lab. Fagan has identified a
number of biomarkers for
Alzheimer’s disease.

medical exploitation,” said Myrtis E. Spencer,
who leads the Knight ADRC’s African-American
outreach program. “But they are twice as likely
to get the disease compared with non-Hispanic
whites. We don’t know why. We don’t have the
full scientific picture because research historically
hasn’t been inclusive.”
Through the efforts of Spencer, Morris and
others, African-American participation in
Alzheimer’s studies at the School of Medicine has
risen to 18 percent, comparable with the AfricanAmerican population in the St. Louis area and
significantly higher than the national average for
Alzheimer’s studies.

8 Washington University School of Medicine

Although treatment is important for the
estimated 5 million Americans already living
with Alzheimer’s, it won’t lead to a future free
of Alzheimer’s. By the time people show up in
doctors’ offices complaining of forgetfulness, their
brains already have begun to atrophy. And while
some of the drugs currently in trials may be able
to prevent more brain cells from dying, nothing
will bring back the cells already lost.
To truly stop Alzheimer’s, doctors must catch
people heading down the path to Alzheimer’s
dementia and redirect them, much as physicians
today measure blood cholesterol levels and, if
necessary, prescribe cholesterol-lowering drugs
to avert a heart attack.
Since the early 1990s, Washington University
researchers have been collecting evidence that
memory loss and confusion show up very late in
the game, after years of toxic protein accumulation
in the brain and corresponding tissue damage.
Two major studies led by Washington University
have used imaging and biomarker analysis to
trace the natural history of the disease: the Adult
Children Study, which follows people with at
least one parent diagnosed with Alzheimer’s, and
the Dominantly Inherited Alzheimer Network
(DIAN), which studies people genetically
predisposed to develop the disease at a young
age. These two studies, and others conducted
at Washington University and elsewhere, have
allowed researchers to develop a rough timeline
of what happens in the brain in the years before
symptoms appear: Amyloid plaques appear first,
then tau tangles, followed by brain atrophy.
“This silent phase may last two decades, which
gives us a chance to intervene,” Morris said.
Spinal taps and PET scans can reliably detect
signs of disease before dementia, but neither is
ideal for widespread screening. A single PET scan
Winter 2018-19

One day, Alzheimer’s disease will be treatable or even
preventable. Researchers at Washington University are
leading the way to making that bright future real.”
			— David C. Farrell, David C. Farrell and his late wife, Betty, made major
Trustee Emeritus

costs approximately $5,000 and requires equipment
and expertise difficult to find outside of research
settings. Spinal taps have an undeserved reputation
for being painful and dangerous, so some patients
are reluctant to undergo the procedures.
MRI scans, though, are already a routine part
of neurological care, available in most clinics.
Benzinger and colleagues have shown that a
characteristic pattern of brain atrophy is visible in
an MRI scan before symptoms appear. They are
developing an MRI scan to diagnose Alzheimer’s
in its pre-symptomatic phase.
A blood test is also on the horizon. “Last year my
lab reported the first highly specific blood test for
amyloid,” said Randall J. Bateman, MD, the Charles
F. and Joanne Knight Distinguished Professor of
Neurology. “Since then, other groups have replicated
and expanded on it. I think we’ll see that test in use
in doctor’s offices in the next three to five years.”
Rajendra S. Apte, MD, PhD, the Paul A. Cibis
Distinguished Professor of Ophthalmology and
Visual Sciences, and Gregory P. Van Stavern, MD,
a professor of ophthalmology and visual sciences,
recently have reported a small study that suggests
that signs of Alzheimer’s might be detectable
through a specialized, noninvasive eye exam.

commitments to establish and enhance the Farrell
Family Alzheimer’s Disease Research Fund, supporting
the research of David M. Holtzman, MD.

but their brains show some amyloid accumulation.
Two drugs are being tested — the trial of a third
was stopped due to safety issues — to determine
whether they can slow amyloid plaque buildup.
The final report is due out in a year.
Although DIAN-TU involves people with rare
mutations, treatments that are successful in this
population could also help people with the more
common forms of the disease, which strike older
adults. It is thought that the destructive processes
in the brain are much the same for both types of
the disease.
Other prevention trials involving people with
genetic forms of Alzheimer’s are in the works.
A few prevention trials are underway in people
without genetic forms of the disease, and more
could be launched once screening tests are more
fully developed. There are plenty of experimental
drugs to try.
Shakespeare lamented the coming of the
“second childishness.” We may be able to
elude it.

Myrtis E. Spencer,
conferring here with
pioneering Alzheimer’s
researcher John C. Morris,
MD, leads an outreach
effort dedicated to ensuring
that African-Americans are
appropriately represented
in Alzheimer’s research.

No longer inevitable
But finding people on the path to dementia is only
half the battle. We also need to find a way to get
them off the path.
Bateman directs the DIAN Trials Unit
(DIAN-TU), an international clinical trial designed
to find drugs that prevent Alzheimer’s dementia.
The trial involves people from DIAN families;
family members who inherit a faulty gene variant
are all but guaranteed to develop Alzheimer’s
dementia at about the same age their parent did,
typically in their 50s, 40s or even 30s. Participants
enroll in the trial while their minds are still sharp
outlook.wustl.edu
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On the frontiers
of psychiatry
Physician-scientists aim to reduce the impact of mental illness on society
BY JIM DRYDEN

Up to one-third of the 16 million Americans with clinical depression
don’t get relief from antidepressant drugs. As a result, they endure
continuing sadness, problems with sleep, and often, difficulty
concentrating, so that reading a book or functioning at work is
problematic. Some even contemplate and attempt suicide. And the
impact extends to family and friends.
10 Washington University School of Medicine
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The Taylor Family Institute, a
collection of several member
research laboratories, is studying
the potential therapeutic
value of natural and synthetic
neurosteroids, which act on
receptors in the brain to affect
cognitive and emotional functions.

outlook.wustl.edu
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In its 25 years of existence,
the YSP has connected with
more than 10,000 students,
encouraging many to consider
STEM (science, technology,
engineering, math) careers.

Steven J. Mennerick, PhD,
prepares to use a collection
of technology — including
a microscope and amplifiers
— to measure the tiny
electrical impulses between
brain cells. The equipment
helps him assess how the
electrical conversations of
neurons are influenced by
therapeutic drugs.

F

or doctors treating patients with depression
and other psychiatric disorders, the reality
is that many of the therapeutic drugs at
their disposal have major limitations — both in
terms of effectiveness and potential adverse side
effects. Not only that, but the last new class of
antidepressant drugs, selective serotonin reuptake
inhibitors (SSRIs) such as Paxil, Zoloft, Lexapro
and Prozac, hit the market 30 years ago.
At Washington University’s Taylor Family
Institute for Innovative Psychiatric Research,
investigators are looking for new solutions. Their
ultimate goal: Reduce suffering and diminish
the impact of psychiatric illnesses on society.
Institute investigators are exploring receptors
in the brain to identify new targets for therapy,
developing potential drug candidates, and partnering
with industry to speed progress. The institute is
on the verge of helping get two investigational
antidepressant drugs to the market, and there
could be other promising compounds in the
pipeline, too.

12 Washington University School of Medicine

Private funding =
fast progress
The institute was created in 2012 through private
funding from the university’s Leading Together
campaign. Its founding mission: to provide flexible
funding to foster and streamline efforts in basic
research, clinical research and drug development
as scientists work across disciplines to uncover
new ways to treat psychiatric illness. Members of
the institute collaborate among several
departments, including psychiatry, anesthesiology,
developmental biology, radiology and neurology.
“The institute really was founded on the
premise that we need flexible funding to support
pipelines of research development, rather than
focusing on individual projects in specific
departments,” said Steven J. Mennerick, PhD, a
professor of psychiatry and of neuroscience and
the institute’s scientific director. “Government
grants tend to be very specific, so to take a project
to the next step, you need another grant, and then
another. But with flexible funding through the
institute, we can partner — quickly — with people
who have expertise in other areas of science or

Winter 2018-19

drug development, and we can make progress
faster than is possible with traditional grants.”
Their work starts with understanding the
genetics and biology of psychiatric illness, as
well as the brain circuits involved. Then, when
basic science reveals a potential new therapeutic
approach, institute investigators can get their
findings into the hands of collaborators in
private industry very quickly, especially
through the institute’s close relationship
with Massachusetts-based biopharmaceutical
company Sage Therapeutics.

A new treatment target
Much of the focus at the institute today is directed
toward a class of compounds called neurosteroids
— chemicals that occur naturally in the brain and
are involved in brain networks used for cognition,
emotion and motivation. Disruptions in
neurosteroid levels can contribute to mood
disorders such as depression, anxiety disorders,
schizophrenia, alcoholism, sleep disorders, chronic
pain, epilepsy and neurodegenerative illnesses
such as Alzheimer’s disease.
p to one-third
of the
Current evidence
suggests that
stress16
and
disorders such
as
depression
affect
neurosteroid
million Americans with
production in the brain, so institute scientists
don’tdepleted
believe that clinical
replacing depression
or enhancing these
steroids may alleviate that stress response to make
get relief from antidepressant drugs.
the brain function more normally.
institute
only has
been around for
AsAlthough
a result,thethey
endure
continuing
a handful of years, some of its members have been
sadness,natural
problems
with sleep,
and for
studying
and synthetic
neurosteroids
several
Thatconcentrating,
work began in 1993,
often,decades.
difficulty
sowhen
that
Douglas F. Covey, PhD, then a professor of
reading biology
a bookand
orpharmacology,
functioningand
at Charles
work
molecular
F.
Zorumski,
MD,
then
an
associate
professor
of
is problematic. Some even contemplate
psychiatry, were part of a Program Project Grant
and the
attempt
suicide.
the (NIH)
impact
from
National
InstitutesAnd
of Health
to
study neurosteroids for their anesthetic effects.
extends to family and friends.
Their process: Covey’s lab synthesized neurosteroid
molecules,
and Zorumski
tested
them in with
brain cells.
For doctors
treating
patients
“In those early days, we mostly were trying to
depression
and other
psychiatric
learn
about whether
these molecules
had anesthetic
effects,
and
if
so,
how
they
might
work,”
saidof the
disorders, the reality is that many
Covey, a professor of developmental biology, of
therapeutic and
drugs
at their They
disposal
have
anesthesiology
of psychiatry.
discovered
that neurosteroids weren’t working through
major limitations — both in terms of
serotonin receptors the way SSRIs did. Instead,
many
were influencing
gamma-aminobutyric
acid
effectiveness
and potential
adverse side
(GABA) receptors, the same neuronal receptors
effects.byNot
only that, but the last new
affected
anesthetics.

U
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class
of antidepressant
selective
Fast-forward
about 20 years.drugs,
By the spring
of
2012,
Covey
had
made
hundreds
of
synthetic
serotonin reuptake inhibitors (SSRIs)
neurosteroids, some of which seemed to have the
such astoPaxil,
Zoloft,
Lexapro
and
potential
alleviate
symptoms
of depression.
And Zorumski, now the Samuel B. Guze Professor,
Prozac, hit the market 30 years ago.
head of the Department of Psychiatry and professor
of neuroscience,
believedUniversity’s
that after yearsTaylor
of making
At Washington
and testing neurosteroids, they had a good handle
Family
Institute
Innovative
on
how the
moleculesfor
interacted
with two types of
receptors
in
the
brain:
GABA
receptors
and excitatory
Psychiatric Research, investigators
glutamate receptors. They could, he thought, be on
areverge
looking
for new
solutions.to Their
the
of identifying
neurosteroids
alleviate
depression and other psychiatric disorders.
ultimate goal: Reduce suffering and
“Some of these neuroactive steroids were potent
anesthetics,
but we
believedofothers
were going to
diminish the
impact
psychiatric
prove to be useful for treating several psychiatric
illnesses on
society.
disorders,”
Covey
said.
But at just about that time, a letter arrived
from NIH announcing that the program project
group was about to lose its funding.
Within a day or two of receiving the bad news,
Zorumski started drafting a new white paper,
attempting to explain the importance and
potential impact of the project he’d been involved
in for two decades.
“It was written around the time that Doug
Covey and I were just starting to interact with
Sage Therapeutics, and it was built around the idea
that we could take neurosteroids — as well as the

I have received notes from people
around the country who have been
impacted by mental illness. They now
have a sense of hope; someone is paying
attention. I want many people to pay
attention, because I think awareness
promotes momentum.”
— Andrew C. Taylor, Life Trustee; Chair,
Leading Together campaign
Andrew C. and Barbara Taylor, and the family’s Crawford Taylor
Foundation, made major commitments to establish and enhance
the Taylor Family Institute for Innovative Psychiatric Research.
Outlook 13

Douglas F. Covey, PhD, left,
Charles F. Zorumski, MD, and
colleagues have spent decades
conducting groundbreaking
research on the therapeutic
potential of neurosteroids.

synthetic molecules that had been developed here
at Washington University — and turn them into
therapies,” he said. “We weren’t entirely sure what
these molecules actually would treat, but epilepsy
was a clear target, so was insomnia, and so was
postpartum depression.”
The proposals in the white paper eventually
received funding, and the Taylor Family Institute
for Innovative Psychiatric Research was born.

On the verge
The results are impressive.
“We’re literally only about six years from
when the institute was created, and there already
could be new drugs coming to market just several
months from now,” said Zorumski, now the
director of the institute.
Sage is seeking Food and Drug Administration
approval of two neurosteroids that it developed
based on Washington University research: an
IV drug called brexanalone to treat post-partum
depression, and an oral drug known as Sage
217 for clinical depression in men and women.
During the Taylor Institute’s first half decade
of existence, its scientists have published more
than 60 scientific papers. They have continued to
prepare new compounds to enlarge the original
set of over 700 compounds, and multiple U.S. and
foreign patents are pending. In collaboration,
investigators at Taylor Institute and Sage are
discovering and applying ways to optimize these
neurosteroids for therapeutic use in humans.
14 Washington University School of Medicine

Covey, who has patented many of the molecules
developed in his lab, served for a time as a partner
at Sage, and Zorumski serves on the company’s
scientific advisory board. As a result, much care
has been taken to avoid conflicts of interest, so a
good deal of the clinical testing of neurosteroid
molecules has occurred at other centers.
But other clinical research is underway at the
institute. For example, institute researchers have
been involved in clinical testing of anesthetic
drugs, such as ketamine and nitrous oxide, as
treatments for depression. Their common goal,
one way or another, is to find new ways to provide
relief to the many individuals, families and friends
living with the effects of psychiatric illnesses.
“The success of the Taylor Family Institute
demonstrates the critical impact of private
philanthropy on Washington University’s efforts to
improve human health,” said David H. Perlmutter,
MD, executive vice chancellor for medical affairs
and the George and Carol Bauer Dean at the
School of Medicine. “The investment to launch the
institute was instrumental in helping our scientists
make discoveries that hold great promise for
ameliorating the burden of mental illness, and
their continued support will bolster our ability to
work on the therapeutic frontiers of psychiatry.”

Charles F. Zorumski, MD, is a scientific advisor for Sage Therapeutics and receives
compensation and stock equity from the company for this role. Research partnerships between Sage Therapeutics and Washington University are managed in
accordance with applicable conflict-of-interest policies and regulations. Douglas F.
Covey, PhD, has an issued patent and pending patents for jointly invented intellectual
property assigned to Washington University and Sage Therapeutics.
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ADVANCES IN TREATING

mental illness
Taylor Family Institute investigators are setting their
sights on a new set of therapeutic targets in the brain.
Their goal: Develop drugs that engage these new targets
and better address depression and other mental illnesses.

Then

Now

Administer selective serotonin
reuptake inhibitors (SSRIs) and
tricyclic drugs, which increase brain
levels of serotonin and promote
feelings of well-being.

Generate and test compounds that augment
the action of gamma-aminobutyric acid
(GABA), which calms key brain cells, and
glutamate, which excites key brain cells.
Seek ways to balance their activities to
achieve well-being.

Target serotonin receptors.

PROS
Existing SSRIs and tricyclics are
effective for many people.

CONS
Drugs can have undesirable side
effects. Up to one-third of patients
are not helped by these drugs.

Serotonin
receptors

outlook.wustl.edu

Target GABA and glutamate receptors.

PROS
The prevalence of, and variations in,
GABA and glutamate receptors may
facilitate targeting specific receptor
classes for more effective therapies.

CONS
The landscape is complex and not
thoroughly understood. Defining a
“normal” balance may be difficult.

GABA
receptors

Outlook 15
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The warrior
within
The future of cancer treatment
BY GAIA REMEROWSKI

A few short decades ago, cancer treatment
consisted mainly of three pillars: surgery,
radiation and chemotherapy. Although
each has earned its place as a valuable
option, more precise alternatives have long
been the oncologist’s dream.
Now, a deeper understanding of the
way our bodies fight disease is launching a
promising new era in which cancer’s worst
enemy may be the warrior within: our
own immune system. By determining the
characteristics of individual tumors at the
genetic and molecular levels, researchers are
tailoring treatment to each patient, aiming
the built-in destructive power of the immune
system directly at cancer.
Robert D. Schreiber, PhD, right, consults with doctoral student
Samuel O. Ameh. Their work exploring the immune system’s
role in controlling cancer is fueling development of a range of
approaches to cancer immunotherapy.
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A seismic shift
Until the early 2000s, researchers only dreamed
that the immune system could be capable of
keeping cancer at bay. Then research at Washington
University and elsewhere began uncovering
evidence that made the dream seem possible.
The shift began in 2001, when Washington
University’s Robert D. Schreiber, PhD, and
colleagues published a landmark paper in Nature
concerning the adaptive immune system — the part
of the immune system that recognizes and destroys
specific disease-causing agents. They showed that
mice lacking adaptive immunity developed more
tumors, showing that conversely, healthy adaptive
immunity restrains cancer development.
His subsequent work demonstrated that tumors
can evolve to evade and resist the adaptive immune
response, which is why cancer can form in people
with intact immunity. So, Schreiber surmised, if we
could retrain the immune system to see cancer, we
might have a new targeted tool to fight the disease.
This research has advanced the latest frontier in
cancer treatment: immunotherapy.
Schreiber leads the Andrew M. and Jane
M. Bursky Center for Human Immunology
and Immunotherapy Programs, where he and
many others are dedicated to translating human
immunology research from the bench to the
bedside. Much of their work has started in animal
models. As he put it: “We’ve cured a lot of mice of
their cancers.” But it’s not only mice who benefit
from the center’s work.
“One of the things that’s been so exciting is
that for the first time we have an opportunity to
take what we’re learning at the bench level and see
it applied to human disease,” said Schreiber, the
Andrew M. and Jane M. Bursky Distinguished
Professor. “That’s what’s so amazing about the
Bursky Center.”

While Schreiber focuses on cancer, others at
the center are applying findings about the immune
system to autoimmune and infectious diseases, such
as diabetes and the flu.
The center’s seminal cancer immunology
research is beginning to move from the lab into
the clinic, thanks to collaborations across the
School of Medicine — and particularly with the
Alvin J. Siteman Cancer Center at Barnes-Jewish
Hospital and Washington University School of
Medicine, where clinical researchers are working
on a variety of ways to harness the immune
system to fight cancer.
“Figuring out how to use the immune system to
target cancer cells and not normal cells is something
many of us have worked on for the last three or four
decades,” said Timothy J. Eberlein, MD, the Spencer
T. and Ann W. Olin Distinguished Professor,
chair of the Department of Surgery and director of
Siteman Cancer Center. “Now something we only
dreamed about is becoming a reality.”

Personalized vaccines
One way to train the immune system to recognize
cancer cells is by using a vaccine. Vaccines work
by injecting parts of the foreign invader — in this
case, cancer cells — into patients. The vaccine
then prompts the immune system to mount an
attack on that invader.
William E. Gillanders, MD, professor of
surgery and Siteman Cancer Center research
member, led one of the earliest human breast
cancer vaccine trials. The vaccine contained a
protein called mammaglobin-A, which is found at
abnormally high levels in almost all breast cancer
cells, making it an easy target for the immune
system. Gillanders and Washington University

The speed at which the center is translating
groundbreaking discovery into new modalities of
personalized treatment is incredibly exciting.”
— Andrew M. Bursky, Trustee
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Andrew M. Bursky and his wife, Jane M. Bursky,
made a significant commitment to name the
Andrew M. and Jane M. Bursky Center for Human
Immunology and Immunotherapy Programs.
Winter 2018-19

colleagues were the first to study the protein in
breast cancer and elicit an immune response to it,
then developed the vaccine based on that work.
The trial results were promising, but
mammaglobin-A also is made by certain
normal cells and can generate an autoimmune
response to them. So Gillanders, Schreiber and
others began searching for other, more tumorspecific vaccine targets.
They found a candidate in proteins called
neoantigens that exist on the surface of cancer
cells. Neoantigens, which Schreiber was among the
first researchers to recognize, are unique to each
patient’s tumor but, importantly, are not present
on normal cells. He and Gillanders reasoned that
the immune system could be trained to recognize
neoantigens as foreign and to destroy cancer cells
without harming normal ones. But the challenge,
said Schreiber, was how to identify each patient’s
unique neoantigens and determine which were
most likely to be recognized by the immune system.
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This is where genome sequencing comes in.
By sequencing patients’ cancer cell genomes and
comparing them to their normal cell genomes,
researchers can determine which neoantigens are
unique to each patient’s tumor and which generate
the strongest immune response. They can then use
those neoantigens to make a personalized vaccine.
Gillanders’ group is testing neoantigen vaccines
in patients with triple negative breast cancer, a
form that is difficult to treat. They are conducting
trials that combine the current standard of care
— surgery, radiation and chemotherapy — with a
vaccine in the hope of preventing recurrence.
“Finding the right way to combine traditional
therapies with immune therapies such as vaccines,
that’s where things are moving,” said Gillanders.
Neoantigen cancer vaccines represent a truly
personalized treatment approach; neoantigens vary
from patient to patient and from tumor to tumor, so
each patient’s vaccine must be made from scratch.
That can present challenges with production.

William E. Gillanders, MD,
senior scientist Xiuli Zhang, MD,
and colleagues have developed
breast cancer vaccines now
in clinical trials. Here, they
examine blood test results
indicating study participants’
response to a vaccine.
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H OW TO MA K E A
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accines work
by co-opting a
disease-causing agent to
generate or rev up an immune
response against that disease.
To avoid harming healthy tissue, a cancer
vaccine must be generated from an agent
unique to cancer cells. Among the promising
candidates are neoantigens — proteins present only
on tumor cells, in combinations unique to each patient.
normal cell

1. Sequence

cancer
vaccine
2. Identify

Sequence the
genomes of the
patient’s normal
and cancer cells.

Using sequencing
data, identify cancer
cell neoantigens
unique to the patient.

3. Prepare vaccine

4. Vaccinate & monitor

cancer cell

Make a vaccine with
the neoantigens and
inject into the patient.

Immune cells now
see tumor cells as
foreign and attack
the cancer.

More ways to treat cancer
CAR-T cell therapy

Checkpoint inhibitors

Monoclonal antibodies

NK cell therapy

Collect patient’s T cells
and engineer them to
recognize and kill cancer.

Use antibodies that block
cell interactions to restore
immune destruction of tumors.

Use antibodies that attach to
cancer cells to make them
visible to the immune system.

Expose patient’s NK
immune cells to chemicals
called interleukins to help
them better fight cancer.

T

T
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The research being conducted at the Siteman Cancer
Center is transforming the way the disease is treated.”
— Alvin J. Siteman,
Trustee Emeritus

During Leading Together, Alvin J. and Ruth Siteman continued
their transformative support for the Alvin J. Siteman Cancer Center
at Barnes-Jewish Hospital and Washington University School of
Medicine, which was named in 1999 in honor of their generosity.

“There aren’t many places that can generate
these products under the kinds of conditions
that you need to make a vaccine,” said Schreiber.
Fortunately, the School of Medicine and
Siteman Cancer Center are home to a Good
Manufacturing Practice (GMP) lab, where
immunotherapies such as cancer vaccines
can be made and tested in clinical trials. Such
facilities, which meet exceedingly high standards
for consistency and quality, are not typical in
most academic medical centers and help keep
costs down when producing such expensive
individualized treatments.

Deploying T cells
Another form of immunotherapy under
investigation at the School of Medicine uses a
patient’s T cells to target certain blood cancers,
such as leukemia, lymphoma and multiple
myeloma. T cells typically fight off disease.
But in some cancer patients, these cells lose the
ability to recognize and attack cancer cells.
“The immune system can’t always see cancer
cells as threats; the T cells are sometimes blind
to them,” said John F. DiPersio, MD, PhD, the
Virginia E. and Sam J. Golman Professor of
Medicine in Oncology and deputy director of
Siteman Cancer Center. “By modifying T cells,
we tell them what to look for so they can go right
to the leukemia or lymphoma and eliminate the
cancerous cells.”
Like the cancer vaccines, this therapy is
individualized for each patient and each tumor.
The T cells, known as Chimeric Antigen Receptor,
or CAR-T cells, are produced in the same GMP
facility where the vaccines are made. They are
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designed and tested by the Center for Gene
and Cellular Immunotherapy (CGCI) in the
Department of Medicine’s Division of Oncology.
DiPersio and colleagues were involved in
clinical trials that led to the Food and Drug
Administration’s approval of CAR-T cell therapy,
and Siteman Cancer Center is now among the first
centers nationwide to offer it to patients. DiPersio’s
team is now working on a way to make a universal
form of CAR-T cells that can come from a donor
rather than the patient. Such an approach could
be faster, less costly and more effective for patients
with rapidly progressing blood cancers. DiPersio
and the CGCI team are attempting to expand
application of current CAR-T to other diseases,
such as T-cell leukemias and lymphomas, acute
myelogenous leukemia and solid tumors.
Also entering the clinic is a new form of
immunotherapy called checkpoint inhibitors.
Checkpoints are proteins on the surface of T cells
that survey proteins on other cells to determine
whether they are normal or diseased. Normal
cells are left alone, and diseased cells are flagged
for destruction. Unfortunately, cancer cells can
display proteins that bind to T cell checkpoints
and trick the T cells so they do not see the
cancer as foreign. Researchers are now devising
antibodies that block the T cell-cancer cell
interactions, making the cancer once again visible
to the immune system.
The 2018 Nobel Prize in Physiology or
Medicine went to James P. Allison, PhD, of the
United States and Tasuku Honjo, MD, PhD, of
Japan, who independently discovered two separate
checkpoint inhibitor pathways. At Washington
University, researchers are using checkpoint
inhibitors in combination with traditional
therapies as well as neoantigen vaccines in
trials for breast, lung and other cancer types.
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Bettina Drake, PhD,
MPH, discusses cancer
prevention at a health
fair in East St. Louis.

A FOCUS ON

cancer disparities
O

ne of the best ways to fight cancer is to stop it before it
starts, and, failing that, make sure everyone has access to
the best possible care. Siteman Cancer Center is working with the
community in and around St. Louis to improve prevention and
screening programs and to reduce cancer care disparities.
At the forefront of these efforts is Bettina Drake, PhD, MPH,
associate director of cancer health equity for Siteman Cancer Center.
Drake, an associate professor of surgery in the Division of Public
Health Sciences, began researching prostate cancer as a doctoral
student at the University of South Carolina, in a state where
African-American men are almost three times more likely to die of
prostate cancer than white men — often due to missed diagnoses.
The survival rate for prostate cancer, if caught early, is normally
95-100 percent.
Soon after her father was diagnosed with prostate cancer,
Drake got involved in community outreach with area churches,
providing educational materials about prevention and screening
for those at risk of getting cancer. “The combination of my
outreach experiences and my father’s diagnosis fueled my
interest and passion in disparities research,” said Drake.
In St. Louis, Drake now leads the Prostate Cancer Community
Partnership, part of the Program for the Elimination of Cancer
Disparities at Siteman Cancer Center. The program seeks to eliminate
screening and treatment barriers to improve patient outcomes.
Drake works with community leaders and colleagues such as
Lannis Hall, MD, MPH, Arnold D. Bullock, MD, and Aimee S. James,
PhD, MPH, to develop public awareness campaigns and refine
identification of high-risk groups. She is also focused on recruiting
a more diverse patient population for Siteman clinical trials.
“When we do research, we want our patient population to
resemble the people who will be receiving the treatment in the
future,” said Drake.
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A new standard
Much of the work on targeted cancer immunotherapies could not have been done without the
Elizabeth H. and James S. McDonnell III Genome
Institute (MGI). In 2008, the institute led a historic
effort to sequence the first entire cancer genome,
of a woman with leukemia, and helped identify the
genetic errors that contributed to her disease. Though
it was an uncertain endeavor at the time, St. Louis
philanthropist Alvin J. Siteman agreed to fund the
project. That work has since established Washington
University as a national leader in the field of cancer
genomics and prompted many clinicians to add
cancer genome sequencing to their standard of care.
A case in point: Nearly every patient with
lung cancer who sees Ramaswamy Govindan, MD,
the Anheuser-Busch Endowed Chair in Medical
Oncology, gets some or all of their genome sequenced.
“We no longer stop at the microscopic level
when diagnosing cancer,” said Govindan, co-leader
of Siteman Cancer Center’s solid tumor program
and a leader in lung cancer clinical trials and
translational research. “Now we do molecular
profiling and study the genes that are altered to see
whether we can use targeted therapies.” Depending
on the situation, that might involve using a targeted
chemotherapy or customized tumor vaccine, either
as part of a clinical trial or as a standard of care.
Govindan’s group is trying to understand the
reasons why cancer cells metastasize or become
unresponsive to medical therapies. He also is using
sequencing to develop a neoantigen vaccine that he
is testing in a trial for patients with non-small cell
lung cancer, the most common form of the disease.

With the research that is
being done, we are getting
so close. The future looks
brighter than ever before.”
— Rodger O. Riney
Paula C. and Rodger O. Riney made a
major commitment to establish the
Paula C. and Rodger O. Riney Blood
Cancer Research Initiative Fund for
multiple myeloma research.
Winter 2018-19

What appeals to us about the institute is its
collaboration with St. Louis Children’s Hospital and
the School of Medicine’s Department of Pediatrics in
the application of genomics to pediatric cancers.”
— James S. McDonnell III

Elizabeth H. and James S. McDonnell III and the JSM Charitable
Trust made an extraordinary commitment to name the
Elizabeth H. and James S. McDonnell III Genome Institute.

Researchers at MGI and elsewhere at the
School of Medicine are making key discoveries
in a number of other cancer types, including
leukemia, aggressive prostate cancer and estrogen
receptor positive breast cancer, one of the most
common forms of that disease. This work is
helping to guide treatment decisions such as
choosing the appropriate chemotherapy or
determining who may be a good candidate for
certain immunotherapies, such as vaccines.
MGI’s sequencing advances, the Bursky
Center’s immunology discoveries and Siteman
Cancer Center’s clinical prowess make for a
powerful combination.
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“The next frontier in cancer research is to apply
our skills in genomics to better characterize the
tumor, its environment and its interaction with
the immune system,” said DiPersio. “That will be
a huge help in understanding the relapsing and
remitting of cancers.”
“The future is going to be pretty amazing
for cancer patients. They’ll have more effective
treatments with fewer side effects, more targeted
therapies, early diagnosis and even ways to prevent
the disease,” said Eberlein. “We’ve been fortunate
to have the partnership of so many donors,
patients and their families, who have recognized
that investing in innovation and research is the
future of cancer care.”

Oncologist John F. DiPersio,
MD, PhD, meets with cancer
patient Stephen Brown.
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Jeffrey I. Gordon, MD, the founder of
microbiome research, is also known as
a dedicated and very influential mentor
who has trained a next generation of
leaders in this field. Carrie A. Cowardin,
PhD, left, and Vanderlene L. Kung,
MD, PhD, are postdoctoral researchers
in Gordon’s lab.
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Probing the
microbiome
Studies of people and their companion microbes
shed light on health and disease
BY J U L I A E VA N G E LO U S T R A I T

Even in our most solitary moments, we
humans are never alone. On us and within us,
tens of trillions of microbes live and thrive —
not as passive hitchhikers, but as interactive,
symbiotic shapers of our biology. From the
time of our births, these microbes are at work,
establishing distinct communities in many
regions of our bodies.
In recent decades, scientists at Washington
University have led the way in exploring how
these microbial communities impact human
health. Their work has shaped a new area of
study that is revolutionizing our understanding
of normal human physiology, metabolism,
immunity, growth and neurodevelopment, as
well as the roots of many diseases.
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David Wang, PhD, right,
and PhD student Luis
Sandoval are studying
viruses in the gut to learn
more about their impact
on health and disease.

A new field emerges
Using the gene sequencing technology of the
genome revolution, along with many other
experimental and computational methods and
tools, researchers worldwide are studying our
microbial companions — considering them not in
isolation, but rather in the context of the complex
communities in which they dwell. Scientists are
learning which microbial members exist in a given
area of the body, what genes they collectively
possess, what their genes do, how community
membership varies from person to person, and
ultimately, how these communities influence
health and disease.
The work has emerged as a new field called
microbiome research, founded by Jeffrey
I. Gordon, MD, the Dr. Robert J. Glaser
Distinguished University Professor and director
of the Edison Family Center for Genome Sciences
& Systems Biology at Washington University
School of Medicine.
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Microbiome is the term given to the collective
repertoire of genes possessed by microbes in a
given community. Microbiomes are massive; the
gut microbiome alone is made up of more than
100 times the number of genes in the human
genome. In 30 years of seminal research, Gordon
has revealed the fundamentals of how these
communities first assemble, how they adapt, how
community members cooperate and compete
with one another, and how they interact with the
human body. What’s more, he and his students
were the first to link the gut microbiome to two of
the world’s most vexing global health problems —
childhood malnutrition and obesity.
“For human societies to flourish, our challenge
is to do everything in our power to promote the
healthy development of children so that they
may realize their full potential,” said Gordon,
also professor of pathology and immunology,
of developmental biology, of medicine and of
molecular microbiology. “There are dramatic
disparities in the abilities of children in different
Winter 2018-19

The Edison family greatly respects Dr. Gordon’s sound
thinking and innovative research. His work has global
importance and appears to be critical to helping
malnourished children throughout the world.”
— Andrew E. Newman, Life Trustee
and Edison family member

parts of the world to live healthy lives. And
somewhere in the midst of this challenge
to promote healthy development sits the
gut microbiome.”

Healthy communities
“No one else was doing this work when Jeff first
started, and he was alone in the wilderness for
a long time. Now, myriad microbiome projects
at Washington University and around the world
have built on Jeff’s science, in part because he has
trained many of the next generation of leaders in
this field,” said Phillip I. Tarr, MD, the Melvin E.
Carnahan Professor of Pediatrics and professor of
molecular microbiology.
Central to the field is learning how
to nurture microbial communities
in ways that enhance human health
— much as one would cultivate the
natural flora and fauna common to a
forest or wetland to support a healthy,
diverse and robust ecosystem. That
ability could have massive public
health implications, including checking
infectious disease, resolving chronic
inflammatory conditions, correcting
metabolic dysfunction, and tackling the
global problems related to the quality
of our diets and nutrition — all at a
time of rapid population expansion
and challenges to environmental
sustainability.
“This is a new frontier,” said Tarr,
also director of the Division of Pediatric
Gastroenterology, Hepatology, and
Nutrition. “The rules are now just
beginning to be written.”
outlook.wustl.edu

The Harry Edison Foundation and the Edison family
made a major commitment to name the Edison
Family Center for Genome Sciences & Systems Biology.

Therapeutic foods
Central to Gordon’s current work is addressing
malnutrition. He and his collaborators at the
International Centre for Diarrhoeal Disease
Research in Bangladesh have shown that
children with malnutrition possess gut microbial
communities that fail to develop normally, leaving
them with communities that appear younger,
or less mature, than those of healthy children.
Moreover, current therapeutic foods do not repair
this immaturity or correct the long-term effects
of malnutrition, including impaired growth,
metabolism, immunity and brain development.
These findings have led his team to develop
new therapeutic foods, composed of affordable,

Medical student
researcher I-Ling
Chiang pulls bacterial
cultures from a freezer
in the lab of Thaddeus S.
Stappenbeck, MD, PhD.
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culturally acceptable components that advance
development of immature gut communities and
improve the health status of malnourished children.
Their work is not only establishing a vital
link between formation of healthy microbial
communities and healthy growth, but also is
revealing how microbial communities transform
components of the foods we consume into
products that influence numerous features of
human postnatal development. At the same
time, food science is revealing more about the
components of various food staples and how plant
genetics and food processing technologies and
consumers’ microbiomes influence the nutritional
content and value of those foods. Together, these
advances should enable discovery, development
and deployment of entirely new health-promoting
foods and better dietary recommendations for
children and their parents, Gordon said.

Preventing disease
Beyond Gordon’s lab, Washington University
microbiome researchers are addressing other topics.
Tarr and colleagues Barbara B. Warner, MD,
professor of pediatrics, and Gautam Dantas, PhD,
professor of pathology and immunology and of
molecular microbiology, for example, are studying

Thaddeus S. Stappenbeck, MD, PhD, right, reviews slides
with postdoctoral fellow Umang Jain, PhD.
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the gut microbiomes of babies born prematurely.
These babies are at risk of developing a potentially
deadly condition called necrotizing enterocolitis,
a progressive inflammatory process that begins
inside the gut and causes tissue death. Sometimes
antibiotics are an effective treatment, but some
babies need surgery to remove dead tissue. Even
with these aggressive therapies, about 30 percent
of babies who develop the disease die from this
catastrophic event.
Tarr and Warner have shown that babies who
develop necrotizing enterocolitis have a different
mix of microbes in their intestines than babies
who never develop the disease.
“We’re still in the earliest stages of defining
which microbes are good and which are bad,” Tarr
said. “But broadly, we want to find out what factors
make it likely for good microbes to get into the gut
and stay and, similarly, what factors help the body
get rid of bad microbes. The hope is to ultimately
protect premature infants from ever developing
this terrible disease.”

The virus hunters
Tarr and his colleagues — including David Wang,
PhD, professor of molecular microbiology and of
pathology and immunology, and Lori R. Holtz,
MD, MSPH, associate professor of pediatrics —
also have studied viruses living in the guts of
healthy newborns. The viruses’ collective genetic
material is called the virome.
“Not only are there many viruses in the
digestive systems of infants that we had no idea
were present, there are viruses that infect the
bacteria in great numbers,” Tarr said. “And this
almost certainly plays a role in how the bacterial
community develops.”
Indeed, the bacteria, viruses and other
microbes in the intestine together offer a picture
of the gut environment that metaphorically
resembles a backcountry wilderness.
And as they explore that wilderness, Wang and
his team have viruses in their sights. Wang seeks
out previously unstudied viruses to understand
how they function and to learn more about how
viruses cause disease.
“We want to understand the nature of the
whole virome and how it may be associated with
health or disease,” Wang said. “We’ve done this
in the context of a number of diseases, including
acute diarrhea, HIV/AIDS, type 1 diabetes and
Winter 2018-19

Barbara B. Warner, MD,
left, Lori R. Holtz, MD,
MSPH, and Phillip I.
Tarr, MD, discuss their
research on gut microbial
communities in premature
and healthy newborns.

inflammatory bowel disease. This has been
fascinating because we had no idea what to expect.”
Working with Thaddeus S. Stappenbeck, MD,
PhD, the Conan Professor of Laboratory and
Genomic Medicine, Wang and colleagues found
that the virome in patients with inflammatory
bowel disease is different than the virome of
healthy people, suggesting viruses may play a
role in the development of this condition.

Guardians of the gut
Stappenbeck’s work examines the interaction of
gut microbes and human gut tissues, including
agents he calls “guardians of the gut.” One such
agent is an antibody called immunoglobulin A,
or IgA. IgA coats gut microbes and may well
calm the response of our immune system to the
microbiome. Another is a cell type in the gut
lining known as Paneth cells.
“These cells protect the inner lining of the
gastrointestinal tract by making a variety of
antimicrobial proteins,” said Stappenbeck, also a
professor of developmental biology and a former
postdoctoral fellow in Gordon’s lab. “In doing so,
they help shape the microbiome present in the gut.
We know that mice with defective Paneth cells can
develop worsened gut inflammation. This suggests
that we can use the genetics of the abnormal
Paneth cells to diagnose the type of inflammatory
bowel disease a patient might have.”
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A better understanding of these guardians and
others may contribute to better ways to diagnose,
treat or prevent inflammatory diseases of the gut.
As scientists study the gut microbiome,
additional complexity reveals itself. But if
researchers can navigate that complexity to
understand and promote a healthy gut ecosystem,
their work may save preemies from a deadly
inflammatory disease, prevent the complications
of obesity, or protect children from the ravages of
malnutrition. Nurturing a healthy gut may be the
next public health revolution.

If we are able to help mitigate suffering
in any way, that’s a larger contribution
to humanity than Debra and I ever
envisioned we would have. We feel very
fortunate that we can do something
that has such potential to help others.”
— George W. Couch III, Trustee
		
Debra and George W. Couch III provided significant
campaign support for research in personalized medicine;
in their honor, the university named the Debra and
George W. Couch III Biomedical Research Building.
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Research technician Ira
Wight, left, and PhD student
Arielle Homayouni examine
microscopic samples related
to autophagy, a natural cell
recycling process.

Emerging areas
New centers address
personalized medicine
and aging
BY CHANNING SUHL

T

hree newly established research centers
will strengthen the School of Medicine’s
commitment to advancing two of the

institution’s major research priorities: personalized
medicine and aging. Investigators in these centers
will undertake multidisciplinary work with implications
for addressing a broad range of major health issues.
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Personalized
cardiovascular care

Aging and age–dependent
degenerative diseases

Despite years of advances in the treatment and
prevention of cardiovascular disease, it remains
the leading cause of death worldwide. Now,
personalized medicine — an innovative approach
based on individual genetics and biomarkers —
has the potential to change the standard of care.
Alumnus Kim D. Kuehner, MBA ’77, has
committed $15 million to establish and endow
the Kim D. Kuehner Program for Personalized
Cardiovascular Medicine in the School of
Medicine. The program will fund competitive
research grants within the school, providing a
permanent source of funding for research aimed
at improving the prevention, diagnosis and
treatment of heart disease.
The complexities of cardiovascular diseases
such as heart failure, atherosclerosis and
cardiomyopathy make developing personalized
medicine approaches challenging. At the center,
researchers hope to elucidate
the mechanisms behind each
disease to enable development of
therapies tailored for certain patient
subgroups — ending the approach
of treating the “average patient.”
Ultimately, clinicians will address
the cause of the disease rather than
the presenting clinical symptoms.
“Individualized patient care strategies have
transformed the care of patients with cancer,”
said Douglas L. Mann, MD, the Tobias and
Hortense Lewin Professor of Medicine and chief
of the Cardiovascular Division. “Thanks to Kim
Kuehner, investigators involved in cardiovascular
disease at Washington University will now have
the opportunity to transform the care of patients
afflicted with heart disease.”
The Kuehner program comes at the perfect
time, as the School of Medicine ushers in the next
phase of its personalized medicine initiative.
“This new program will allow us to leverage our
leadership in personalized medicine to develop
tailored approaches to cardiovascular disease,”
said David H. Perlmutter, MD, executive vice
chancellor for medical affairs and the George and
Carol Bauer Dean of the School of Medicine. “Mr.
Kuehner’s exceptional generosity and deep interest
in addressing a significant health challenge will
benefit patients around the globe.”

Sima Needleman and Philip Needleman, PhD,
former chair of the Department of Pharmacology,
have committed $15 million to establish the Sima
and Philip Needleman Center for Autophagy
Therapeutics and Research and the Philip and
Sima Needleman Center for Neurometabolism and
Axonal Therapeutics. The combined research efforts
are expected to foster development of novel therapies
for multiple diseases and impact neurodegenerative
diseases of aging such as Alzheimer’s.
“Part of my vision for this school is to have a major
impact on aging. It touches research underway in
every department,” said Perlmutter. “These centers
will support us in advancing shared priorities and
making progress towards real, measurable outcomes.”
The Center for Autophagy Therapeutics and
Research, led by Perlmutter, will focus its efforts on
autophagy — the mechanism by which cells break
down and recycle their contents. Recent studies

“These centers will support us in advancing
shared priorities and making progress towards
real, measurable outcomes.” — David H. Perlmutter, MD
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show that exercise and caloric restriction promote
autophagy, resulting in better health and increased
longevity. But when the process becomes impaired,
which is increasingly likely with age, abnormal
cellular activity can lead to cancer, diabetes and
neurological disorders.
The Center for Neurometabolism and Axonal
Therapeutics will be led by Jeffrey Milbrandt,
MD, PhD, James S. McDonnell Professor and
head of the Department of Genetics, and Aaron
DiAntonio, MD, PhD, Alan A. and Edith L. Wolff
Professor of Developmental Biology. Building on
recent breakthroughs in understanding how nerves
degenerate, the center will explore the intersection
of metabolism, inflammation and degeneration
in the nervous system in order to develop novel
therapies for neurological diseases.
Needleman began his career at the School of
Medicine in 1964 as a postdoctoral fellow and
later held several pivotal roles there. He spent 14
years at Monsanto, later Pharmacia LLC, heading
pharmaceutical research and development. Building
on research begun at Washington University, he led
the development of the arthritis drug Celebrex.
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Campaign
summary
A successful campaign is supporting scientists,
teachers and learners as they change the future of
medicine locally and around the globe.

$44.5M

$1.54M

Annual Fund

Other

supporting teachers
and learners

$56.8M
Facilities

supporting
capital
improvements

$360M

Faculty Endowment: $36
supporting endowed profe

Endowment: $4
Faculty Student
supporting endowed stude
Endowment



Programs: $1,
supporting Academic
supporting critical program
endowmentFacilities: $56.8M
research andsupporting
faculty capital improve

Total raised

Annual Fund: $44.5M
supporting teachers and le
Other: $1.54M

$1.34 B

$47.7M

Academic
Programs

Student
Endowment

supporting endowed
student scholarships

supporting critical
programs and research

Agency/Group: 1

RESEARCH The Debra and George W. Couch III Biomedical Research Building,

Donors


named in recognition of significant campaign support from Debra and George
W. Couch III, is home to numerous research initiatives and centers, including the
Edison Family Center for Genome Sciences & Systems Biology, the Center for Cellular
Imaging, the Center for Multiple Myeloma Nanotherapy, the Optical Radiology Lab
and the Molecular Imaging Center.

Alumni: 11,846

Corporation: 2,8

Foundation: 395

Individual: 46,75
Parent: 1,722
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supporting critical programs and research

professorships

Facilities: $56.8M
supporting capital improvements

Total raised

Annual Fund: $44.5M
supporting teachers and learners
Other: $1.54M

1,805

1,722

Agency/Group

Parent

Agency/Gro

11,846
46,756

Alumni

Individual

2,876

Donors


Donors

Endowed

Agency/Group: 1,805
Alumni: 11,846

professorships

Corporation: 2,876

Corporation

Endowed professorships
established during the campaign
included a named deanship, making
David H. Perlmutter, MD, the inaugural George
and Carol Bauer Dean of the School of Medicine.

Foundation: 395

395

Individual: 46,756

Foundation

Parent: 1,722

JANA HOLSTEIN

Scholarship

funds raised





Scholarship funds raised
78

olarships

FY 2009
FY 2018

Including the George and Carol Bauer Dean of the
School of Medicine. The inaugural recipient is
H. Perlmutter, MD, also Spencer T. and Ann
EDUCATION Medical students Tiffany J. Wu, Jason A. Morris, David
Students
W. Olin Distinguished
Professorsupported
and executive vice
Jae Lee and Jane M. Hayes, all Distinguished Alumni Scholarship chancellor for medical affairs
174

180
recipients, are among hundreds of graduate students at the
School of Medicine supported by 281
scholarship donations.

281

351

olarships
180
351

PATIENT CARE The School of
Medicine’s patient care mission has
flourished during the 10-year campaign
period, which ended in summer 2018.
The number of clinical practice sites
grew from 35 to 49, clinical revenues
nearly doubled, and two 12-story
towers — carefully designed to support
patient comfort and optimal care —
opened on the Medical Campus, offering
facilities for patients of Siteman Cancer
Center and the Women & Infants Center.
Here, Alison Cahill, MD, visits patient
Susan Zeid.
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Individual: 4

Parent: 1,72

Including the Ge
School of Medici
David H. Perlmut
W. Olin Distingui
chancellor for me

180

2009
2018

Foundation:

Endowed

Endowed Endowed
professorships
scholarship funds

d funds

Corporation



Scholarship funds raised
Annual named scholarship funds
33
86

Alumni: 11,8
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CLASSNOTES

1960 S
Harvey Michael “Mike” Jones, MD ’66,
was elected vice president of the American
Osler Society and will serve a three-year
term, including one year as president.
The American Osler Society is a history
of medicine organization that seeks
to advance a humanistic approach to
medicine. A retired clinical professor of
pathology and laboratory medicine at the
University of North Carolina at Chapel Hill,
Jones also recently was selected by high
school classmates in Winters, Texas, as a
distinguished alumnus.

1970 S

Marilyn Escobedo,
MD ’70, stepped down
after nearly 40 years as a
division chief of neonatal
perinatal medicine at
the University of Texas,
San Antonio, and then
at the University of
Oklahoma. She became professor emeritus
in fall 2017. Escobedo was named a 2018
Distinguished Alumnus at Baylor University,
where she completed her undergraduate
study. Escobedo spends summers in East
Hampton, N.Y., and winters in San Antonio.
Barbara Seaworth, MD ’77, a professor of
medicine at The University of Texas at Tyler,
has been awarded grants exceeding $30
million in the last 10 years, the most recent
from the Centers for Disease Control and
Prevention (CDC) in 2018. She is director of
the Heartland National Tuberculosis Center
in San Antonio, Texas. The CDC recognized
Seaworth as a 2018 National Physician
TB Champion for treating patients and
providing education programs to caregivers
who treat the disease. She was named
by the San Antonio Business Journal as a
2018 Health Care Hero. Seaworth was in
the Marshall Islands during summer 2018
to screen for and treat tuberculosis in that
island nation. She also runs marathons and
tries to keep up with her six children and
husband, John Seaworth, MD ’76, as well
as their six grandchildren.
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Gregorio A. Sicard, MD, HS ’78, professor
emeritus of surgery at WUSM, was awarded
the Lifetime Achievement Award from the
Society for Vascular Surgery in 2018. Sicard
was on the WUSM faculty for more than
three decades and started the vascular
surgery section in 1983, the first year the
American Board of Surgery certification in
vascular surgery became available. Under
Sicard’s leadership, the section grew from
performing fewer than 300 procedures
annually to becoming a globally recognized
center in endovascular patient care and
research. He retired in 2015.
Richard L. Wahl, MD ’78, HS ’83, received
the 2018 Georg Charles de Hevesy Award
from the Society of Nuclear Medicine and
Molecular Imaging. The award recognizes
researchers whose groundbreaking
discoveries have advanced nuclear
medicine.

1980 S

Nancy L. Bartlett, MD ’86, the Koman Chair
in Medical Oncology at WUSM, has been
named a 2018 Legacy Leadership Award
honoree by the Gateway Chapter of the
Leukemia & Lymphoma Society.

1990 S

Bradley L. Schlaggar, MD/PhD ’94, HS ’96,
HS ’99, has been named president and CEO
of the Kennedy Krieger Institute in Baltimore,
Md. The institute works to improve the lives
of children and adolescents with disorders
and injuries of the brain, spinal cord and
musculoskeletal system. He spent 19 years
on the WUSM faculty; during his tenure, he
served as director of the pediatric neurology
residency program, division head of pediatric
and developmental neurology, neurologistin-chief at St. Louis Children’s Hospital,
and co-director of the Intellectual and
Developmental Disabilities Research Center.
Julie Miller, MD ’96, has been living
in Melbourne, Australia, since finishing
surgical training in 2001. Miller, an
academic endocrine surgeon, recently was
elected president of Australian and New

Zealand Endocrine Surgeons, and also the
Asian Association of Endocrine Surgeons.
This is the first time a woman has led either
organization. She is married with three
children, ages 12, 14 and 15.
Jamey Gordon, PT ’97, DPT ’07, is director
of athlete development and a partner at
Pro X Athlete Development in Westfield,
Ind. Pro X specializes in sports performance
training, skill development, rehabilitation
and recovery in all sports. The partners
planned to open a 55,000-plus-square-foot
facility in late 2018 in Westfield, Ind. Gordon
will continue to serve as a clinical instructor
and fellowship mentor for the Program in
Physical Therapy at WUSM.

2000 S

Armand Antommaria, MD ’00, was
promoted to professor in the Department
of Pediatrics at Cincinnati Children’s
Hospital Medical Center and the University
of Cincinnati School of Medicine. He is the
director of the Ethics Center at Children’s.
Emily Bannister,
LA ’96, MD ’01, and
her husband, David,
welcomed twins Abigail
and David to their family
in April 2017. They join
big sister, Lucy, born
in July 2015. Bannister
is an attending in the HealthPartners
Occupational Medicine residency program
in St. Paul, Minn., and serves as medical
liaison for laboratory biosafety at the
University of Minnesota.
Katie Grover, DOT ’03, and her husband,
Ben, welcomed a child, Mason, Jan. 6, 2018.
Brian J. DeBosch, MD/PhD ’08, is one
of five faculty members at the School
of Medicine elected to the Society for
Pediatric Research, which aims to improve
child health through research, professional
collaboration and advocacy.

2010 S

Kristin Haider Chumbley, AuD ’10, was
married June 22, 2018.
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Danielle Doria Braman,
OT ’11, announces the
birth of her first daughter,
Elliana, on March 15,
2018. Braman is working
at Children’s Hospital
Colorado.
Ian Glenn, MD ’12, and Tara Glenn,
MD ’12, welcomed a daughter, Nora
Mary, on July 14, 2018.
Jennifer Yu, EN ’08, MD ’12, MPHS ’15,
a general surgery resident at WUSM and
Barnes-Jewish Hospital, has received a
2018 Outstanding Resident Teacher Award
from the Association for Surgical Education.
Yu’s award recognizes her enthusiasm,
effectiveness and commitment to teaching
surgical skills to medical students and
other residents.
Samuel Nemanich, MS/PhD ’16, is
listed as co-principal investigator on a
grant awarded from the National Center
of Neuromodulation for Rehabilitation,
a National Institutes of Health (NIH)funded project. Nemanich and his wife,
Sarah Wahlstrom Helgren, PhD ’16,
also welcomed their second child, Lucille,
on July 25, 2018.
Brandon Holmes,
MD/PhD ’17, married
Diane Snyder, OT ’10,
on April 14, 2018. Both
work at the University of
California, San Francisco,
where Brandon is a
neurology resident
physician and Diane is a practicing
occupational therapist.
Matthew McCoy,
PhD ’18, and
Amy Herbert, PhD ’18,
were married
June 30, 2018.
The couple met at
Washington University
while working on PhDs
in biology and biomedical sciences.
They are Grass Fellows in Neuroscience
at the Marine Biological Laboratory in
Woods Hole, Mass., and will be moving
to Stanford University in fall 2018 as
postdoctoral researchers.
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Joseph J. Billadello, MD, a professor of medicine and director
of the Adult Congenital Heart Disease Center, died Wednesday,
Aug. 8, 2018, following a long battle with multiple myeloma.
He was 65.
Billadello came to Washington University in 1981 as a
cardiology fellow and joined the School of Medicine faculty,
where, over his long career, he cared for patients with heart
disease, especially adults living with congenital heart disease. He also helped lead
several organizations focused on treating individuals born with heart defects who
survive to adulthood and require specialized care.
“Joe’s leadership of the Adult Congenital Heart Disease Program culminated in the
designation of the Washington University program as an accredited comprehensive
care center by the Adult Congenital Heart Association, one of only a few such centers
in the nation,” said Victoria J. Fraser, MD, the Adolphus Busch Professor and head of
the Department of Medicine. “Joe was passionate about patient care, and that is
reflected in the quality of care he and his colleagues provided.”
Billadello earned a medical degree from Georgetown University School of
Medicine in 1978. He completed an internship and residency in internal medicine
at Duke University before coming to Washington University for fellowship training.
He is survived by his wife, Guadalupe Sanchez, MD; mother, Julia “Peggy”
Billadello; sister, Joan Quinn; daughter, Laura Billadello, MD; and son-in-law,
Michael DeVita, MD.
John O. Holloszy, MD, whose research led to advances in
the understanding of the body’s response to exercise, died
Wednesday, July 18, 2018, in Town and Country, Mo., following
a long battle with kidney disease. He was 85.
A 1957 alumnus of the School of Medicine, Holloszy
went on to train as a postdoc at the school under Nobel
laureate Carl F. Cori, MD. In 1973, Holloszy became the director
of the school’s Division of Applied Physiology in the Department of Preventive
Medicine, and later served as director of the Division of Geriatrics and Gerontology
in the Department of Medicine. He retired from the university in 2017.
Holloszy’s studies of aerobic exercise, nutrition and muscle development
changed the way elite athletes train and helped others better cope with heart
disease, diabetes, obesity and aging.
Holloszy also discovered that exercise improved insulin sensitivity in patients
with type 2 diabetes, and that exercise training could reverse some of the damage
in patients with coronary heart disease. In key animal studies, Holloszy found that
calorie restriction lengthened the animals’ lives even more than exercise.
“John Holloszy is considered the father of modern exercise biochemistry,” said
Samuel Klein, MD, the William H. Danforth Professor of Medicine and Nutritional
Science and director of the Division of Geriatrics and Nutritional Science.
In 2000 at the Olympic Games in Sydney, the International Olympic Committee
presented Holloszy with a gold medal, the IOC Olympic Prize in Sports Medicine,
for his contributions to understanding the science behind enhanced athletic
performance and disease state management.
Born in Vienna, Holloszy earned a bachelor’s degree in 1953 at Oregon
State University.
Holloszy is survived by his wife, Violetta, and a brother, Fred.
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J. Russell Little, MD, professor emeritus of medicine, died Saturday,
Aug. 18, 2018, in St. Louis following a long illness. He was 87.
Little served on the School of Medicine faculty from 1964 to 2005
and as chief of infectious diseases at Jewish Hospital from 1967 to 1996.
He was known for his dedication to teaching, mentoring and
patient care. In 2017, the Division of Infectious Diseases established
the J. Russell Little Award for Excellence in Teaching in his honor.
“His compassion and expertise were remarkable, and he was a
significant reason why the infectious diseases program here is one of the best in the
country,” said William G. Powderly, MD, the Larry J. Shapiro Director of the Institute of
Public Health and co-director of the Division of Infectious Diseases.
Little helped characterize the structure of antibodies and contributed to an
understanding of how they recognize their targets. He also studied how the fungus
Histoplasma survives inside immune cells, and showed that the antifungal medication
amphotericin B changes the behavior of the immune system.
He earned a medical degree from the University of Rochester and completed a
medical residency at Barnes Hospital in 1957. Following a research appointment at the
National Institutes of Health (NIH), he returned to St. Louis as chief resident at Barnes Hospital.
He is survived by his daughters, Nancy Little and Susan Little; son, Bryan Little; and
four grandchildren.
Necita Llorin-Roa, MD,
a practicing anesthesiologist in St. Louis for
nearly 50 years, died of
natural causes Sunday,
May 27, 2018, at St. Luke’s
Hospital in Chesterfield,
Mo. She was 74.
After graduating from the University of
the Philippines Manila College of Medicine
in 1969, she completed an anesthesia
residency and fellowship at Barnes-Jewish
Hospital and the School of Medicine in
1973-1974.
A renowned educator and clinician and
a beloved colleague, Roa was an associate
professor of anesthesiology and served on
the Washington University faculty for 42
years. She endowed the Necita Roa Award
for the best graduating anesthesiology
resident as well as a fund to support global
health programs for anesthesiology
trainees. Since 2014, Roa was president of
the Philippine Medical Association of the
Greater St. Louis Medical Foundation Inc.,
leading six annual medical and surgical
missions to underprivileged communities in
her home country of the Philippines.
The widow of the late microbiologist
Renan C. Roa, who immigrated with her
from the Philippines to the U.S. in 1969, Roa
is survived by her brothers Carlos Llorin Jr.
and Manuel Llorin and sister Marilu Arellano.
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James C. Warren, MD,
professor emeritus and
former head of the
Department of Obstetrics
and Gynecology, died
Saturday, July 21, 2018,
at his home in Mobile,
Ala. He was 88.
Warren, a renowned researcher, clinician
and teacher, was noted for his work in the
endocrinology and biochemistry of
reproduction. One of Warren’s most
important research contributions was
identifying and determining the significance
of progesterone, a hormone that is an
essential part of birth control pills.
Warren earned a medical degree from the
University of Kansas in 1954. Following an
internship at the University of Kansas
Medical Center, he served as a physician in
the U.S. Navy for two years. Warren then
completed a residency in obstetrics and
gynecology and a doctorate in biochemistry,
both at the University of Nebraska. For 10
years, he served as a professor of obstetrics
and gynecology and of biochemistry at the
University of Kansas School of Medicine. He
joined the School of Medicine faculty in 1971
and served as a department head until 1989.
He is survived by his wife, Margie; his
sister, Kay Ross; three children, Jamie
Warren Corkran, James Douglas Warren and
Allison Warren; and nine grandchildren.

1940 S
Richard Bell, DE ’46; July ’18
Martha Benedict, OT ’47; June ’18
Virginia P. Hagemann, NU ’48; July ’18
Homer H. Hanson, HS; Apr. ’18
Richard C. Lyon, DE ’47; Apr. ’18
Ruth Portman Steele, OT ’48; Aug. ’18

1950 S
David J. Edwards, MD ’57; July ’18
Stephen M. Harris, HS ’54; Apr. ’18
Frank A. Howard, MD ’50; Apr. ’18
Daniel B. Lowrey, MD ’50; June ’18
Muriel MacKallor, OT ’53; Apr. ’18
Morris Reichlin, LA ’55, MD ’59; July ’18
Joseph Sanker, DE ’55; Apr. ’18
Richard L. Swarm, LA ’49, MD ’50; June ’18
Paul D. Tinnin, DE ’54; July ’18
Milton M. Tofle, LA ’51, DE ’55; Aug. ’18
Stephen L. Washburn, MD ’52; June ’18

1960 S
Ray Bowman Duncan, HS ’65; June ’18
Darlene A. Feser, NU ’64, GN ’66; July ’18
Cleveland M. McCarty, DE ’61; July ’18
Paul K. Orsay, HS ’67; May ’18
Robert E. Smith, DE ’63; June ’18

1970 S
Clinton N. Corder, MD ’71; Apr. ’18
Steven Levitt, LA ’66, DE ’70; June ’18
Michael O. Williams, MD ’74; Aug. ’18

1990 S
Darlene Eyster, LA ’75, HS ’95; June ’18
David M. Peeples, HS; June ’18

For full obituaries, visit:
wumcnews.org/obits
Correction: Jacquelyn Carter Kremer, OT ’97,
was incorrectly listed among the deceased in
the Fall 2018 Outlook issue.
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CAMPAIGN LEADERSHIP
SCHOOL OF MEDICINE
Campaign Co-Chairs
GEORGE W. COUCH III
Trustee, Washington University
DAVID C. FARRELL
Emeritus Trustee, Washington University
GORDON W. PHILPOTT, MD ’61, HS
Former Chief of Surgery, Jewish Hospital
Former Trustee, Washington University

Committee Members
ANDREW CHAN, MD/PhD ’86, HS ’89
Senior Vice President, Genentech
ROBERT G. CLARK
Chairman and CEO, Clayco Corporation
PETER CORR, PhD
Co-Founder, Auven Therapeutics Management LLLP
LOUIS KUCHNIR, PhD, MD ’97, HS
Private Practice Physician
JAMES S. MCDONNELL III

PHILIP NEEDLEMAN, GR ’99
Emeritus Trustee, Washington University
WILLIAM A. PECK, MD, HS ’63
Director, Center for Health Policy
Former Executive Vice Chancellor
and Dean, School of Medicine
SHIRLEY SAHRMANN, PT ’58, MA ’71, PhD ’73, HS
Professor Emeritus of Physical Therapy,
School of Medicine
HARVEY SALIGMAN*
Trustee, Washington University
CRAIG D. SCHNUCK
Chairman, Schnucks Markets Inc.
Trustee, Washington University
SALLY SCHNUCK, OT ’78
WILLIAM P. WIESMANN, MD ’72, HS
President and Founder, BioSTAR Group
Trustee, Washington University
PAMELA GALLIN YABLON, AB/BS ’74, MD ’78
Director, Pediatric Ophthalmology,
Professor of Pediatrics,
Columbia Presbyterian Medical Center

SITEMAN CANCER CENTER
Honorary Chair
ALVIN J. SITEMAN, GR ’00
Chairman, Site Oil Company of Missouri
Emeritus Trustee, Washington University

Chair
ROBERT F. O’LOUGHLIN
Chairman and CEO, Lodging Hospitality Management
Emeritus Trustee, Washington University

Committee Members
RONALD A. FROMM
President and CEO, Fashion Footwear Association
of New York
MICHAEL STAENBERG
Founder, The Staenberg Group
MARGARET A. AND JERRY E. RITTER
St. Louis Community Volunteers
JOANNE P. KNIGHT, GR ’96, GR ’10
* Deceased
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